Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 9/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067916 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL1051267 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL102246 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL5487802 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL4560704 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL16875635 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL7514132 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL9125832 | 0.74 | KDR (0.62) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL877269 | 0.72 | DYRK1A (0.50) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL8933370 | 0.72 | DYRK1A (0.50) | DYRK1ACLK4MAPK14MAP4K4PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852154-A | Carboxamide substituted hetero tricyclic derivative, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4219453-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-2802576-B1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2015168286-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARAITON AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | DYRK1A 1271/4885CLK4 2151/4885MAPK14 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.